Biodegradation of metal-based ultra-small nanoparticles: A combined approach using TDA-ICP-MS and CE-ICP-MS.
Biodegradation
Capillary electrophoresis
Gadolinium containing drug
Inductively coupled plasma mass spectrometry
Taylor dispersion analysis
Ultrasmall nanoparticles
Journal
Analytica chimica acta
ISSN: 1873-4324
Titre abrégé: Anal Chim Acta
Pays: Netherlands
ID NLM: 0370534
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
received:
11
06
2021
revised:
15
09
2021
accepted:
16
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
3
11
2021
Statut:
ppublish
Résumé
The knowledge of the fate of metal-containing nanoparticles in biological media in aqueous media is of utmost importance for the future use of these promising theranostic agents for clinical applications. A methodology based on the combination of TDA-ICP-MS and CE-ICP-MS was applied to study the degradation pathway of AGuIX, a phase 2 clinical ultrasmall gadolinium-containing nanoparticle. Nanoparticle size measurements and gadolinium speciation performed in different media (phosphate buffer, urine and serum) demonstrated an accelerated dissolution of AGuIX in serum, without any release of free gadolinium for each medium.
Identifiants
pubmed: 34711326
pii: S0003-2670(21)00907-7
doi: 10.1016/j.aca.2021.339081
pii:
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339081Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FL and OT have to disclose the patent WO2011/135101, that protects the AGuIX® NPs described in this publication. PR, TD, FL and OT are employees from NH TherAguix that is developing the AGuIX nanoparticles and possess shares of this company.